HoLEP after prostate biopsy: does it have any impact?


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 10 08 2020
accepted: 30 10 2020
pubmed: 14 11 2020
medline: 12 1 2022
entrez: 13 11 2020
Statut: ppublish

Résumé

Holmium laser enucleation of the prostate (HoLEP) has recently become the recommended treatment for prostate in all sizes in benign prostate hyperplasia surgery. A recent prostate biopsy performed prior to the HoLEP procedure can make surgeons concerned about the surgery. We aimed to investigate the per- and postoperative outcomes of the HoLEP procedure in patients who underwent prostate biopsy and to evaluate the most appropriate surgery time after biopsy. The data of 160 patients who underwent HoLEP by a single surgeon between March 2017 and December 2019 were retrospectively reviewed. The patients were divided into two groups, Group 1 consisted of 80 patients without prostate biopsy and Group 2 consisted of 80 patients with prior prostate biopsy. All HOLEP procedures in group 2 were performed at least 2 weeks following biopsy. Per- and postoperative outcomes, complications were evaluated. No significant differences were found between groups in terms of by enucleation time, efficiency of laser, efficiency of enucleation, hospitalization time, and catheterization removal time. Only morcellation time was shorter in biopsy naïve patients. There were no statistical differences in postoperative outcomes. Previous prostate biopsy did not affect the continence status in our study group. There were not any Clavien grade 4 or higher complications. Urinary tract infection was higher in early post-biopsy period, there was no difference among the groups. CONCLUSıON: Our study confirms that HoLEP is a safe and efficient surgical procedure for the patients with prior prostate biopsy. We believe that it can be safely performed 2nd week following prostate biopsy.

Identifiants

pubmed: 33185708
doi: 10.1007/s00345-020-03518-z
pii: 10.1007/s00345-020-03518-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2605-2611

Informations de copyright

© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Herlemann A, Wegner K, Roosen A, Buchner A, Weinhold P, Bachmann A, Stief CG, Gratzke C, Magistro G (2017a) “Finding the needle in a haystack”: oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP). World J Urol 35(11):1777–1782. https://doi.org/10.1007/s00345-017-2048-y
doi: 10.1007/s00345-017-2048-y pubmed: 28516315
Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, McVary KT (2019) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2019. J Urol 202(3):592–598. https://doi.org/10.1097/ju.0000000000000319
doi: 10.1097/ju.0000000000000319 pubmed: 31059668 pmcid: 31059668
Gazel E, Kaya E, Yalcin S, Aybal H, Aydogan TB, Tunc L (2019) Comparison of the efficacy of holmium laser enucleation of the prostate in treating prostate volumes of ≤ 80 and > 80 mL. Urol Int 102(3):306–310. https://doi.org/10.1159/000496173
doi: 10.1159/000496173 pubmed: 30731471 pmcid: 30731471
Krambeck AE, Handa SE, Lingeman JE (2010) Holmium laser enucleation of the prostate for prostates larger than 175 grams. J Endourol 24(3):433–437. https://doi.org/10.1089/end.2009.0147
doi: 10.1089/end.2009.0147 pubmed: 19852722 pmcid: 19852722
Vincent MW, Gilling PJ (2015) HoLEP has come of age. World J Urol 33(4):487–493. https://doi.org/10.1007/s00345-014-1443-x
doi: 10.1007/s00345-014-1443-x pubmed: 25416347
Zhuo J, Wei HB, Zhang F, Liu HT, Zhao FJ, Han BM, Sun XW, Xia SJ (2017) Two-micrometer thulium laser resection of the prostate-tangerine technique in benign prostatic hyperplasia patients with previously negative transrectal prostate biopsy. Asian J Androl 19(2):244–247. https://doi.org/10.4103/1008-682x.168790
doi: 10.4103/1008-682x.168790 pubmed: 26732107
Shi YF, Mo NX, Shi HL, Wang XG, Wu B, Lü Z (2019) Transurethral holmium laser enucleation of the prostate for benign prostatic hyperplasia in patients with a history of transrectal prostate biopsy. Natl JAndrol 25(5):403–407
Bell C, Moore SL, Gill A, Obi-Njoku O, Hughes SF, Saleemi A, Ellis G, Khan F, Shergill IS (2019) Safety and efficacy of Holmium laser enucleation of the prostate (HoLEP) in patients with previous transperineal biopsy (TPB): outcomes from a dual-centre case-control study. BMC Urol 19(1):97. https://doi.org/10.1186/s12894-019-0523-z
doi: 10.1186/s12894-019-0523-z pubmed: 31640663 pmcid: 6805368
Tunc L, Yalcin S, Kaya E, Gazel E, Yılmaz S, Aybal HC, Yılmaz M, Tokas T (2020) The “Omega Sign”: a novel HoLEP technique that improves continence outcomes after enucleation. World J Urol. https://doi.org/10.1007/s00345-020-03152-9
doi: 10.1007/s00345-020-03152-9 pubmed: 33185708
Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59(4):477–494. https://doi.org/10.1016/j.eururo.2010.12.009
doi: 10.1016/j.eururo.2010.12.009 pubmed: 21195536
Mottet N, Cornford P, van den Bergh RCN, Briers E, De Santis M, Fanti S (2020) Prostate cancer. EAU 2020 guidelines. p 33
Kumar V, Abbas AK, Aster JC (2014) Robbins and Cotran pathologic basis of disease. In: Kumar V, Abbas AK, Aster JC (ed) Inflammation and repair, Chap 3, 9th edn. Elsevier, Philadelphia, pp 106–107
Bostwick DG (1997) Evaluating prostate needle biopsy: therapeutic and prognostic importance. CA Cancer J Clin 47(5):297–319. https://doi.org/10.3322/canjclin.47.5.297
doi: 10.3322/canjclin.47.5.297 pubmed: 9314824
Elkoushy MA, Elshal AM, Elhilali MM (2015) Incidental prostate cancer diagnosis during holmium laser enucleation: assessment of predictors, survival, and disease progression. Urology 86(3):552–557. https://doi.org/10.1016/j.urology.2015.06.002
doi: 10.1016/j.urology.2015.06.002 pubmed: 26216838

Auteurs

Sercan Yılmaz (S)

Department of Urology, Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.

Engin Kaya (E)

Department of Urology, Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.

Eymen Gazel (E)

Department of Urology, Acıbadem University Ankara Hospital, Ankara, Turkey.

Serdar Yalcın (S)

Department of Urology, Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.

Halil Cagrı Aybal (HC)

Department of Urology, Kahramankazan Hamdi Eris State Hospital, Ankara, Turkey.

Mehmet Yılmaz (M)

Department of Urology, Zile State Hospital, Kahya Mahallesi Ata Caddesi No: 1 Zile, 60400, Tokat, Turkey. yilmazmehmet88@hotmail.com.

Onur Açıkgöz (O)

Department of Urology, Pendik State Hospital, Istanbul, Turkey.

Hakan Özdemir (H)

Department of Radiology, Diason Ultrasonography Center, Ankara, Turkey.

Lutfi Tunc (L)

Department of Urology, Gazi University School of Medicine, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH